2018
DOI: 10.3892/or.2018.6567
|View full text |Cite
|
Sign up to set email alerts
|

Developing a radiosensitivity gene signature for Caucasian patients with breast cancer

Abstract: Adjuvant radiotherapy is an important clinical treatment option for patients with breast cancer. However, for Caucasian patients, the clinical benefit of adjuvant radiotherapy can differ from African‑American patients with respect to the overall survival. The goal of the current study was to develop a gene signature and to pre‑identify patients likely to benefit from radiotherapy. Using publicly available breast cancer data from The Cancer Genome Atlas, a new cross‑validation procedure was proposed for develop… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
4
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
7

Relationship

3
4

Authors

Journals

citations
Cited by 7 publications
(4 citation statements)
references
References 32 publications
0
4
0
Order By: Relevance
“…In the present study, radiosensitive patients were defined as a group of patients who had better overall survival after receiving radiotherapy compared with nonradiotherapy. Radiosensitive gene was defined as the genes which are associated and could be used to identify the radiosensitive patients [ 17 ]. The genes involved in the PD-L1 pathway in cancer were found in the Kyoto Encyclopedia of Genes and Genomes (KEGG).…”
Section: Methodsmentioning
confidence: 99%
“…In the present study, radiosensitive patients were defined as a group of patients who had better overall survival after receiving radiotherapy compared with nonradiotherapy. Radiosensitive gene was defined as the genes which are associated and could be used to identify the radiosensitive patients [ 17 ]. The genes involved in the PD-L1 pathway in cancer were found in the Kyoto Encyclopedia of Genes and Genomes (KEGG).…”
Section: Methodsmentioning
confidence: 99%
“…In the present study, radiotherapy sensitivity was defined as the improved survival benefits of the patients receiving radiotherapy, compared with the patients who did not receive radiotherapy [22, 23]. The gene that can predict individual radiosensitivity could be a potential biomarker for radiosensitivity prediction.…”
Section: Data Sources and Methodsmentioning
confidence: 99%
“…Seven studies used TCGA data only to generate signatures for soft tissue sarcoma (STS) (n = 2) [17,18], gastric cancer (n = 1) [19], HNSCC (n = 2) [20,33], breast cancer (n = 1) [24] and cervix cancer (n = 1) [35]; four of these used a cross-validated adaptive signature design (CVASD) approach to derive and validate the signature within the same dataset, two split the TCGA cohort into training and validation and one used the TCGA to validate a signature derived in a very small independent cohort. The remaining five studies used multiple publicly available microarray/RNA-Seq cohorts to derive signatures for breast cancer (n = 4) [14,25,32,36] and glioma/glioblastoma (n = 1) [39].…”
Section: Other In Vivo Derived Radiosensitivity Signaturesmentioning
confidence: 99%